Adderall XR Cost in Washington 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Cash Price of Adderall XR in Washington in 2026?

Generic mixed amphetamine salts extended-release capsules average around $30 per month at Washington retail pharmacies when patients use a free discount card such as GoodRx or RxSaver. Without any discount, the same generic can run $80 to $120 per month, while the brand-name Adderall XR carries a manufacturer list price near $260 per month.

Price variation across Washington is real. A 30-capsule supply of 20 mg generic mixed amphetamine salts XR quoted at Costco Pharmacy in Kirkland may differ by $15 to $25 from the price at a Fred Meyer in Spokane. Calling ahead or using an online comparison tool before filling any prescription takes less than five minutes and can save a meaningful amount over a year of treatment.

The FDA maintains a current list of approved amphetamine salt products and their manufacturers on its Orange Book database [1]. Switching between generic manufacturers is generally considered therapeutically equivalent under FDA bioequivalence standards, though individual patients occasionally notice differences in clinical effect and should discuss any concerns with their prescriber [2].

Mixed amphetamine salts are Schedule II controlled substances under the Controlled Substances Act, meaning no automatic refills are permitted and prescriptions must be issued for a defined supply, typically 30 days at a time [3]. Washington State follows federal Schedule II rules without additional state restrictions on day supply for ADHD indications.

The MTA Cooperative Group trial (Arch Gen Psychiatry, 1999; N=579) remains the landmark study establishing that stimulant medication produces significantly better ADHD symptom control than behavioral therapy alone or community care, with 56% of the medication-management group rated as normalized at 14 months versus 34% in the behavioral-treatment group [4]. That evidence base is why consistent monthly access to medication matters clinically, and why cost barriers have real patient-care consequences.

Does Washington Medicaid Cover Adderall XR?

Washington Apple Health, the state's Medicaid program, covers mixed amphetamine salts extended-release for both ADHD and narcolepsy indications, but prior authorization (PA) is required. The PA process asks the prescriber to document the diagnosis, confirm the patient meets age and diagnostic criteria, and in some cases show that an immediate-release amphetamine formulation was trialed first.

Once PA is approved, enrolled Apple Health members typically pay a $1 to $3 copay per fill, or nothing at all under the most comprehensive managed-care plans. The Washington State Health Care Authority publishes its preferred drug list (PDL) and PA criteria online, and prescribers can submit PA requests electronically through the ProviderOne portal [5].

Medicaid managed-care organizations (MCOs) operating in Washington, including Molina Healthcare of Washington, Community Health Plan of Washington, and Coordinated Care, each manage their own formularies within Apple Health guidelines. A drug covered under the Apple Health PDL is generally covered by each MCO, but the specific step-therapy requirements can differ slightly. Patients whose PA is denied have the right to appeal, and the Washington Office of the Insurance Commissioner provides guidance on the appeals process [6].

Children under 19 enrolled in Apple Health face no cost-sharing at all for covered prescription drugs under federal Medicaid rules, making stimulant access essentially free for pediatric patients who qualify [7].

Which Commercial Insurance Plans Cover Adderall XR in Washington?

Most commercial plans sold on the Washington Healthplanfinder exchange, as well as employer-sponsored plans, place generic mixed amphetamine salts on Tier 1 or Tier 2 of the formulary. Tier 1 copays in Washington typically run $0 to $15 per fill; Tier 2 copays run $25 to $50 per fill for a 30-day supply.

Brand-name Adderall XR, where still dispensed, lands on Tier 3 or Tier 4 at most major insurers, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Molina Healthcare commercial plans. A Tier 3 copay commonly ranges from $45 to $75 per fill before the deductible is met, dropping after the deductible clears.

The Affordable Care Act requires that non-grandfathered plans cover mental health and substance use disorder services at parity with medical and surgical benefits [8]. ADHD is classified as a mental health condition under ICD-10 (F90.x), which means insurers cannot apply more restrictive cost-sharing to ADHD medications than they apply to analogous medical drugs.

Patients whose plan still requires a PA for generic mixed amphetamine salts should ask their prescriber to submit documentation referencing the diagnosis code, prior treatment history, and, where applicable, results of a validated rating scale such as the Adult ADHD Self-Report Scale (ASRS) or the Conners' Rating Scale. The American Academy of Child and Adolescent Psychiatry practice parameter and the American Psychiatric Association both endorse stimulants as first-line pharmacotherapy for ADHD, which strengthens the clinical justification included in any PA letter [9].

Is Compounded Mixed Amphetamine Salts Legal in Washington?

Compounded mixed amphetamine salts are legally available in Washington State through DEA-registered 503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner, as permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act [10].

Because amphetamine salts are Schedule II controlled substances, 503A compounding pharmacies must hold a DEA Schedule II registration and comply with Washington State Board of Pharmacy rules in addition to federal requirements. The Washington State Pharmacy Quality Assurance Commission (PQAC) licenses and inspects compounding pharmacies operating in the state [11].

Compounded mixed amphetamine salts are not FDA-approved products. They lack the bioequivalence data that generic manufacturers must submit, and the inactive ingredient profile may differ from commercially manufactured capsules. The FDA has stated that compounding of Schedule II drugs is permissible under 503A when a valid patient-specific prescription exists and the drug is not compounded in commercially available doses in a way that essentially copies an approved product [12].

Patient cost for compounded mixed amphetamine salts through HealthRX-affiliated 503A pharmacies is currently $0 per month for qualifying patients, compared to the $30 average cash price for generic Adderall XR at retail and the $260 list price for brand. This cost difference is the primary reason compounded formulations have grown in patient interest during the ongoing generic amphetamine shortage.

The FDA first placed amphetamine extended-release capsules on the drug shortage list in 2022, and as of early 2025 certain strengths remain intermittently short at retail pharmacies [13]. Compounded alternatives filled that gap for some patients, though prescribers should reassess the need for a compounded formulation whenever the commercially manufactured product returns to consistent availability at a patient's local pharmacy.

Can I Get Adderall XR via Telehealth in Washington?

Telehealth prescribing of Adderall XR is permitted in Washington for established patients under the DEA's current rules. During the COVID-19 public health emergency, DEA temporarily allowed Schedule II prescriptions via telemedicine for new patients without an in-person evaluation. A final rule extending those flexibilities for patients with existing prescriptions has been in place; new patients seeking a first-time stimulant prescription via telehealth face stricter requirements that the DEA continues to refine through rulemaking [14].

Washington's own telehealth laws are among the more permissive in the country. The state's parity law (RCW 48.43.735) requires that commercial insurers reimburse telehealth services at rates comparable to in-person visits, which lowers out-of-pocket costs for patients using telehealth platforms to manage ADHD [15].

A telehealth prescriber in Washington must hold a Washington State medical license (or an applicable license under the interstate medical licensure compact), conduct a clinically appropriate evaluation, and document the prescription in a manner that satisfies both DEA and Washington State Board of Pharmacy requirements. Prescriptions for Schedule II drugs may be transmitted electronically under Washington law, provided the prescribing software meets DEA EPCS (Electronic Prescribing for Controlled Substances) standards [16].

Patients using HealthRX's telehealth platform in Washington complete a structured intake that includes validated ADHD symptom screening, a medication and medical history review, and a synchronous video visit with a licensed clinician before any stimulant prescription is generated.

What Discount Programs Are Available for Adderall XR in Washington?

Several cost-reduction pathways exist for Washington residents paying cash for mixed amphetamine salts.

Free discount cards are the fastest option. GoodRx, RxSaver, and NeedyMeds aggregate negotiated prices from pharmacy benefit managers and display the lowest price at nearby pharmacies. These cards are accepted at virtually every major Washington retail chain, including Rite Aid, Walgreens, CVS, Walmart, Kroger (Fred Meyer), and Costco. Presenting the card at the counter lowers the generic price to the $25 to $35 range at most locations.

Manufacturer savings programs apply mainly to brand-name Adderall XR, which Teva Pharmaceuticals has historically offered through its savings card program. Patients with commercial insurance may qualify for a co-pay card that reduces their out-of-pocket cost to as low as $30 per fill for up to 12 fills per year. Patients covered by federal or state government programs, including Medicaid and Medicare, are not eligible for manufacturer co-pay cards under federal anti-kickback rules [17].

The Washington State Prescription Drug Program (no longer accepting new members as of 2024) previously offered negotiated discount pricing through the Department of Health. Patients who lose access to that program can use the NeedyMeds drug discount card as a direct replacement with similar savings at most pharmacies [18].

The HealthRX Cost Decision Framework for Washington patients works as follows. Patients with active commercial insurance should first check their plan formulary for generic mixed amphetamine salts and apply a manufacturer co-pay card if the generic is on Tier 2 or higher. Patients on Apple Health should confirm PA status and fill at an Apple Health-contracted pharmacy. Uninsured patients or those with coverage gaps should compare GoodRx pricing at three local pharmacies before filling, then ask their HealthRX clinician whether a compounded formulation through a 503A pharmacy is clinically appropriate given their diagnosis, prior medication history, and the current availability of commercial product.

How Does the Generic Shortage Affect Washington Patients in 2026?

Amphetamine extended-release capsule shortages have created persistent access problems since late 2022. The FDA's drug shortage database listed multiple amphetamine salt products as in shortage through 2024, and spot shortages at individual Washington pharmacies remain possible into 2026 [13].

The root causes identified by the FDA include DEA production quotas for Schedule II drugs, manufacturer capacity constraints, and increased diagnosis rates following expanded telehealth prescribing during the pandemic. The DEA sets an aggregate production quota for amphetamine annually, and manufacturers must apply for individual quotas; demand growth that outpaces quota adjustments creates supply gaps [19].

Washington patients experiencing a shortage at their usual pharmacy have three practical options. First, call two or three alternative pharmacies in the area to check stock of the specific strength needed. Second, ask the prescriber whether a different strength combination (for example, two 10 mg capsules instead of one 20 mg capsule) is available and clinically acceptable. Third, discuss with the prescriber whether a compounded mixed amphetamine salts formulation from a licensed 503A pharmacy is appropriate as a bridge during the shortage period.

Switching to a different stimulant class, such as methylphenidate extended-release (Concerta, Ritalin LA) or a non-stimulant such as atomoxetine (Strattera) or viloxazine (Qelbree), is a clinical option that some prescribers and patients choose when amphetamine access is unreliable. The American Academy of Pediatrics 2019 ADHD clinical practice guideline supports methylphenidate as an equivalent first-line option to amphetamine salts for school-age children, backed by decades of comparative trial data [20].

What Clinical Evidence Supports Mixed Amphetamine Salts for ADHD?

The evidence base for mixed amphetamine salts is one of the most studied in child and adult psychiatry. The MTA Cooperative Group trial (N=579 to 14 months) found that carefully managed stimulant medication reduced ADHD combined-type symptoms significantly more than behavioral treatment alone or routine community care. Specifically, 56% of the medication-management group showed normalization of ADHD symptoms at 14-month follow-up, compared to 34% in the behavioral-treatment arm [4].

For adults, a 2017 Cochrane systematic review of amphetamines for ADHD in adults (27 randomized controlled trials; N=5,111) found that amphetamines improved ADHD symptoms with a standardized mean difference of 0.79 (95% CI 0.62 to 0.95) over placebo, though they were associated with higher rates of insomnia and decreased appetite [21].

The FDA approved Adderall XR (mixed amphetamine salts extended-release) for ADHD in children 6 to 17 years old and subsequently for adults. The prescribing information specifies starting doses of 5 to 10 mg once daily in children and 20 mg once daily in adults, with titration to effect [22].

Long-term safety data come partly from naturalistic follow-up of MTA participants. At the 8-year follow-up, Molina et al. (2009, J Am Acad Child Adolesc Psychiatry) reported that childhood stimulant treatment did not independently predict substance use outcomes in adolescence, countering a common patient and parent concern [23].

Blood pressure and heart rate monitoring remain standard of care during stimulant therapy. The American Heart Association issued a scientific statement in 2008 recommending baseline and follow-up cardiovascular evaluation for children on stimulant medications, and the FDA label for Adderall XR carries a warning regarding cardiovascular risk in patients with pre-existing structural cardiac abnormalities [24].

Dosing and Administration Basics for Washington Prescribers and Patients

Adderall XR capsules are taken once daily in the morning. The extended-release mechanism delivers approximately 50% of the dose immediately and 50% over the following four hours, providing coverage for roughly 10 to 12 hours. Capsules may be swallowed whole or opened and the beads sprinkled onto a small amount of applesauce, which must be consumed immediately without chewing [22].

Doses range from 5 mg to 30 mg once daily for children 6 to 12, from 10 mg to 30 mg once daily for adolescents 13 to 17, and commonly from 20 mg to 60 mg per day for adults (though 60 mg exceeds the labeled maximum and requires documented clinical justification). Titration typically occurs in 5 to 10 mg increments at weekly intervals.

Food does not significantly alter total amphetamine absorption but does delay the time to peak plasma concentration by approximately one hour. Patients who take the capsule with a high-fat breakfast may notice a slight delay in onset [22].

Acidic beverages, including ascorbic acid (vitamin C) drinks, can lower amphetamine blood levels by increasing urinary excretion of the ionized form of the drug. Patients should avoid large amounts of citrus juice around the time of their dose [25].